• 1
    American Cancer Society Board of Directors. ACS Challenge Goals for U.S. Cancer Mortality for the Year 2015. Atlanta: American Cancer Society; 1996.
  • 2
    von Eschenbach AC. NCI sets goal of eliminating suffering and death due to cancer by 2015. J Natl Med Assoc. 2003; 95: 637639.
  • 3
    Cancer control objectives for the nation. J Natl Cancer Inst Monogr. 1986; 2: 311.
  • 4
    Edwards B, Brown M, Wingo P, et al. Annual report to the nation on the status of cancer; 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97: 14071427.
  • 5
    Byers T, Mouchawar J, Marks J, et al. The American Cancer Society challenge goals. How much can cancer rates decline in the US by the year 2015? Cancer. 1999; 86: 715727.
  • 6
    CurryS, ByersT, HewittM, editors. Fulfilling the Potential of Cancer Prevention and Early Detection. Bethesda: National Cancer Policy Board, Institute of Medicine; 2003.
  • 7
    U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. CDC WONDER [online data]. Available at:
  • 8
    National Center for Health statistics. Health Interview Survey data. Available at:
  • 9
    Hersh A, Stefanick M, Stafford R. National use of postmenopausal hormone therapy. JAMA. 2004; 291; 4753.
  • 10
    Buist D, Newton K, Miglioretti D, et al. Hormone therapy prescribing patterns in the United states. Obstet Gynecol. 2004; 104: 10421050.
  • 11
    Haas J, Kaplan C, Gerstenberger E, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004; 140: 184188.
  • 12
    Kochanek K, Murphy S, Anderson R, Scott C. Deaths: Final Data for 2002. National Vital Statistics Reports. Vol 53, no. 5. Hyattsville: National Center for Health Statistics; 2004.
  • 13
    Anderson R, Minino A, Hoyert D, Rosenberg H. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. National vital statistics reports, vol 49, no. 2. Hyattsville: National Center for Health Statistics, 2001.
  • 14
    National Center for Health Statistics. Data accessed by website. Available at:
  • 15
    United States Census Bureau. Online data. Available at:
  • 16
    Writing Group for the Womens Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. JAMA. 2002; 288: 321333.
  • 17
    Etzioni R, Berry K, Legler J, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991-1998. Urology. 2002; 59: 251255.
  • 18
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 19
    Gohagan J, Prorok P, Hayes R, et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000; 21( 6 Suppl): 251S272S.
  • 20
    Warner E, Mulshine J. Lung cancer screening with spiral CT: toward a working strategy. Oncology. 2004; 18: 564587.
  • 21
    Thun M, Heath C. Aspirin use and reduced risk of gastrointestinal tract cancers in the American Cancer Society prospective studies. Prev Med. 1995; 24: 116118.
  • 22
    International Agency for Cancer Research. Weight control and physical activity. Handbook no. 6. Lyon: IARC Press, 2002.
  • 23
    Mokdad A, Bowman B, Ford E, et al. The continuing epidemic of obesity and diabetes in the United States. JAMA. 2001; 286: 11951200.
  • 24
    Couzin J. Clinical trials. Halt of Celebrex study threatens drug' future, other trials. Science. 2004; 306: 2170.
  • 25
    Meyerhardt J, Mayer R. Systemic therapy for colorectal cancer. N Engl J Med. 2005; 352: 476487.
  • 26
    Winawer S, Zauber A, Ho M, et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med. 1993; 329: 19771987.
  • 27
  • 28
    Cram P, Fendrick A, Inadomi J, et al. The impact of celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med. 2003; 163: 16011605.
  • 29
    Berry D, Cronin K, Plevritis S, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 17841792.
  • 30
    United States General Accounting Office. Mammography: capacity generally exists to deliver services. Report to the Chairman, Special Committee on Aging, U.S. Senate. Washington, DC: United States General Accounting Office, 2002.
  • 31
    Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her-2 positive breast cancer. N Engl J Med. 2005; 353: 16591672.
  • 32
    ATAC Trialists' Group. Results of the ATAC trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 6062.
  • 33
    Wickerham D. Tamoxifen versus Raloxifene in the prevention of breast carcinoma. Eur J Cancer. 2002; 38: s20s21.
  • 34
    Potosky A, Feuer E, Levin D. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev. 2001; 23: 181186.
  • 35
    Feuer E, Merrill R, Hankey B. Cancer surveillance series: interpreting trends in prostate cancer part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999; 91: 10251032.
  • 36
    de Koning H, Auvinen A, Berenguer Sanchez A, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer. 2002; 97: 237244.
  • 37
    Thompson I, Goodman P, Tengen C, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215224.
  • 38
    Unger J, Thompson I, LeBlanc M, et al. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer. 2005; 103: 13751380.
  • 39
    Zeliadt S, Etzioni R, Kristal A. Re: estimated impact of the Prostate Cancer Prevention Trial on population mortality [correspondence]. Cancer. 2005; 104: 15561557.
  • 40
    Lippman S, Goodman P, Klein E, et al. Designing the Selenium and Vitamin E Clinical Trial (SELECT). J Natl Cancer Inst. 2005; 97: 94102.
  • 41
    Duffield-Lillico AJ, Dalkin BL, Reid ME, et al., Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003; 91: 608612.
  • 42
    Virtamo J, Pietinen P, Huttenen J, et al. Incidence of cancer and mortality following alpha tocopherol and betacarotene supplementation: a post-intervention follow-up. JAMA. 2003; 290: 476485.
  • 43
    Pienta K, Smith D. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005; 55: 300318.
  • 44
    Pegram M, Pietras R, Bajamonde A, Klein P, Fyfe G. Targeted therapy: wave of the future. J Clin Oncol. 2005; 23: 17761781.
  • 45
    Jerant A, Franks P, Jackson J, Doescher M. Age-related disparities in cancer screening: analysis of 2001 behavioral risk factor surveillance system data. Ann Family Med. 2004; 2: 481487.
  • 46
    DeMichele A, Putt M, Zhang Y, Glick J, Norman S. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast cancer: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer. 2003; 97: 21502159.
  • 47
    National Center for Health Statistics. Health, United States, 2004. With chartbook on trends in the health of Americans. Hyattsville: National Center for Health Statistics, 2004.
  • 48
    Healthy People 2010. Available at:
  • 49
    Singh G, Miller B, Hankey B, Edwards B. Area Socioeconomic Variations in U.S. Cancer Incidence, Mortality, Stage, Treatment and Survival, 1975-1999. National Cancer Institute; Cancer Surveillance Monograph Series, no. 4. NIH Pub. No. 03-5417. Bethesda, MD: National Cancer Institute; 2003.
  • 50
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 7893.
  • 51
    Trans-HHS Cancer Health Disparities Progress Review Group. Making cancer health disparities history. Report submitted to the Secretary, US Department of Health and Human Services. Washington, DC: U.S. Department of Health and Human Services; 2004.
  • 52
    National Center for Health Statistics. National vital statistics reports, vol 53, no. 15. Hyattsville: National Center for Health Statistics; 2005.